ClinicalTrials.gg
Not yet recruitingNCT07167524EPICUpdated Sep 11, 2025

Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam

An observational study in Sepsis and Severe Bacterial Infections, sponsored by University Hospital, Rouen. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by University Hospital, Rouen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Sepsis with a site in France — 41 open to participants now, 46 under way, 5 of them phase 3. Sepsis · France.

Planned enrollment
90th of 97
24 · median 170
Started
2025
with 9 others
Observational
97 of 209
20 open now
Primary completion
2027-10
later than 29 of 45 live
Registered
195th of 209
by date
Lead sponsor
6 of 209
University Hospital, Rouen

Among the 209 studies in Sepsis with a site in France, this one is the 90th largest by planned enrollment of the 97 observational ones that give a count, is one of 10 that started in 2025, is one of 97 observational ones, reaches primary completion later than 29 of the 45 other live ones, and was the 195th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

41 of the 209 studies in Sepsis with a site in France are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Sepsis with a site in France, or all of them as a file.
02

Study summary

Severe bacterial infections, often responsible for sepsis and septic shock, are a major challenge in critical care: approximately 50% of patients are affected, with a mortality rate of up to 40%. Their initial management consists of antibiotic therapy with an adapted spectrum of activity and dose. One of the most widely used antibiotic therapies in intensive care is the piperacillin-tazobactam (pip-taz) combination, a beta-lactam combined with a beta-lactamase inhibitor, which is indicated probabilistically in many infections (pneumopathies, intra-abdominal infections, urinary tract infections, etc.). Mortality rates of up to 40%. Their initial management consists of antibiotic therapy with an appropriate spectrum of activity and dose. One of the most widely used antibiotic therapies in intensive care is the piperacillin-tazobactam (pip-taz) combination, a beta-lactam combined with a beta-lactamase inhibitor, which is indicated probabilistically in many infections (pneumonia, intra-abdominal infections, urinary tract infections, etc.).

Intensive care patients with septic shock exhibit specific pharmacokinetics with an increased volume of distribution, notably due to significant capillary leakage, often disrupted hepatic metabolism, possible hypoalbuminemia, the presence of renal hyperclearance in the initial phase or conversely, the onset of renal failure with altered glomerular filtration rate, sometimes leading to extrarenal clearance, changes that have consequences for the efficacy and toxicity of the administered antibiotic therapy. Sepsis itself also causes renal dysfunction, with the main pathophysiological hypotheses being an alteration of microcirculation, cellular metabolic reprogramming, and deregulation of the inflammatory response. It is therefore essential to focus on the dosages administered and the pharmacokinetics of these patients. Indeed, underdosing is associated with the emergence of resistance and a poorer prognosis in intensive care patients: increased risk of treatment failure, length of stay and mortality. Conversely, significant overdoses can be associated with a poorer renal prognosis, seizures, encephalopathy which can lead to delayed awakening, prolonged duration of mechanical ventilation and intensive care stay.

Read the detailed description

Pip-taz is administered intravenously due to non-absorption via the oral route. It is weakly bound to plasma proteins (21%), inducing good clearance of extrarenal clearance (fraction extracted in 4 hours: 23.6% of the administered dose). Its plasma half-life is 60 minutes. This molecule is not metabolized, and is therefore independent of liver function. It is eliminated mainly in active form in the urine (65%) and bile (35%). Thus, the main determinant of pip-taz clearance is renal clearance, or continuous extrarenal clearance (CER) in dialysis patients in intensive care.

Pip-taz is characterized by time-dependent pharmacodynamics, with better coverage with continuous infusions compared to discontinuous infusions. However, there is no well-defined pattern in patients undergoing continuous extra-renal purification. Despite recommendations regarding antibiotic dosages for use in intensive care, the lack of data regarding patients undergoing continuous renal replacement therapy (CRRE) remains a major and complex problem in optimizing treatment, as these patients present with unique pharmacokinetics, with an increased risk of treatment failure and mortality. Furthermore, there has been a change in practices in recent years, with pip-taz being administered by continuous infusion and increasingly less by discontinuous infusion, in accordance with the latest recommendations.

To our knowledge, few studies have examined the pharmacokinetics of the pip-taz combination in patients undergoing cCRRE in intensive care. Most of these rare studies did not use standard pip-taz dosages, did not examine the clinical and biological variables influencing pip-taz clearance, and none have examined the impact of any preserved diuresis. Furthermore, there are no data on the kinetics of tazobactam in this population. It therefore seems relevant, given the frequent use of this antibiotic therapy in patients undergoing cERE, to accurately assess the clearance of piperacillin and tazobactam in this population. From a precision medicine perspective, these data could contribute to the construction of a pharmacokinetic model using a population approach, based on blood, urine, and effluent samples, in order to provide a tool to assist in the prescription of this antibiotic therapy in intensive care to reduce iatrogenicity and optimize its effectiveness.

03

Conditions studied

  • Sepsis
  • Severe Bacterial Infections

Keywords

  • medical resuscitation
  • antibiotic therapy
  • clearance of piperacillin and tazobactam
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing continuous extra-renal purification (CER) in the various intensive care units of the Rouen University Hospital (surgical, medical, cardiac surgical), receiving concomitant antibiotic therapy with piperacillin-tazobactam (initiated before or after CER) for sepsis or septic shock.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient over 18 years of age;
  • Patient admitted to intensive care with a prescription for cREV (CVVH (pre- or post-dilution (convection)), CVVHD (diffusion), CVVHDF);
  • Diagnosed or suspected infection sensitive to the piperacillin-tazobactam combination administered by continuous infusion as part of the patient's standard care;
  • Concomitant prescription of piperacillin-tazobactam and cREV;
  • Patient affiliated with a social security scheme;
  • Adult who has read and understood the information letter and has not expressed non-opposition. Due to the potential life-threatening emergency, if the patient is unable to express their non-opposition, the consent of a trusted person or, where applicable, relatives will be sought.

Exclusion criteria

Exclusion Criteria:

  • Documented or suspected allergy to penicillins;
  • Opposition from the patient or trusted person;
  • Pregnant, childbirth, or breastfeeding woman;
  • Minor patient;
  • Person deprived of liberty by an administrative or judicial decision;
  • Person placed under judicial protection, guardianship, or curatorship.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • BiologicalDosage concentration of piperacillin and tazobactam

    The concentration of piperacillin and tazobactam will be quantified by liquid chromatography coupled with tandem mass spectrometry (HPLC-MS² - CIC-CRB 1404) at each of these times by transposition of the method already used in current practice.

06

What researchers measure

Primary outcomes

  1. Determination of continuous extrarenal clearance (CERC) of piperacillin in patients with infection in intensive care

    The cERC clearance of piperacillin will depend on the type of cERC used, thus determining a clearance: * diffusion (dialysis, continuous venomous hemodialysis (CVVHD)), * convection (filtration, continuous venomous hemofiltration (CVVH)), * diffusion and convection (dialysis and filtration, continuous venomous hemodiafiltration (CVVHDF)). Each of these clearances will be characterized by different formulas, based on the collection of the following parameters: pre- and post-filter concentrations, concentration in the dialysate/filtrate/effluent, cERC flow rate for diffusion and convection, hematocrit, and partition coefficient of the substance between whole blood and plasma.

    Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)

Secondary outcomes

  1. Determination of EERc clearance of tazobactam

    The cERC clearance of tazobactam will depend on the type of cERC used, thus determining a clearance: - diffusion (dialysis, continuous venomous hemodialysis (CVVHD)), - convection (filtration, continuous venomous hemofiltration (CVVH)), - diffusion and convection (dialysis and filtration, continuous venomous hemodiafiltration (CVVHDF)). Each of these clearances will be characterized by different formulas, based on the collection of the following parameters: pre- and post-filter concentrations, concentration in the dialysate/filtrate/effluent, cERC flow rate for diffusion and convection, hematocrit, and partition coefficient of the substance between whole blood and plasma.

    Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)

  2. Evaluation of total clearance of piperacillin in patients with preserved residual diuresis.

    The total clearance (CLT) of piperacillin will be determined by considering that they correspond to the sum of the renal clearance (CLR) and the clearance of the EERc (CLEERc). Thus, CLT = CLR + CLEERc. In the absence of diuresis, CLR=0 will be considered and therefore CLT = CLEERc.

    Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)

  3. Evaluation of total clearance of tazobactam in patients with preserved residual diuresis.

    The total clearance (CLT) of tazobactam will be determined by considering that they correspond to the sum of the renal clearance (CLR) and the clearance of the EERc (CLEERc). Thus, CLT = CLR + CLEERc. In the absence of diuresis, CLR=0 will be considered and therefore CLT = CLEERc.

    Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)

  4. Description of the evolution of plasma concentrations of piperacillin over time.

    Plasma concentrations of piperacillin over time will be evaluated using a population pharmacokinetic model using a nonlinear mixed-effects regression model.

    Time frame: At 36 hours

  5. Description of the evolution of plasma concentrations of tazobactam over time.

    Plasma concentrations of tazobactam over time will be evaluated using a population pharmacokinetic model using a nonlinear mixed-effects regression model.

    Time frame: At 36 hours

  6. Development of a dosage regimen to optimize the benefit/risk balance

    A dosage regimen to optimize the benefit/risk balance in this population will be developed by plotting the probability curves of reaching the therapeutic target (PTA) as a function of increasing MICs. The pharmacodynamic indices of efficacy retained will be the fraction of time where the free piperacillin concentration is greater than 1x the MIC (fT \> 1xMIC = 100%) and 4x the MIC (fT \> 4xMIC = 100%).

    Time frame: At 36 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The data provided will be the property of the sponsor and will be used solely for its own research activities.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2027, 24 months later.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 24 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 11, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07167524
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Sep 11, 2025

Study contacts

Camille CR RENARD, Doctor
Contact
Domitille.Renard@chu-rouen.fr
02 32 88 33 27 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion